Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Targeted immune therapy with gemtuzumab ozogamicin (Mylotarg) in combination with
chemotherapy followed by allogeneic stem cell transplantation will be given to patients with
high risk acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).